Skip to main content
. 2022 Oct 28;13:1030642. doi: 10.3389/fphar.2022.1030642

TABLE 3.

The results from base-case analysis.

Total cost ($) Total life years (QALY) Incremental cost ($) Incremental life years (QALY) ICER ($ per QALY)
HFrEF population
 Empagliflozin group 5,501.48 4.27 827.52 0.15 5,612.06
 Control group 4,673.96 4.12
HFpEF population
 Empagliflozin group 5,916.20 4.96 1,271.27 0.11 11,312.65
 Control group 4,645.23 4.85